Trial
NCT02337387
A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Eli Lilly and Company
Collaborators
—
Condition
Osteoporosis, Postmenopausal
Intervention
Blosozumab
Why stopped
Protocol stopping criteria (safety) were met.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-01-22